Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Non Operating Income of $444000.0 for Q1 2026, up 346.67% year-on-year from $99403.0 in Q1 2025, and up 122.36% on a QoQ basis from -$2.0 million in Q4 2025.
Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Non Operating Income for 13 consecutive years, with $444000.0 the latest figure, recorded in Q1 2026.
- Quarterly Non Operating Income rose 346.67% year-over-year to $444000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$402000.0 (down 132.19% YoY) and the FY2025 annual result came in at -$1.0 million, down 155.4% from the prior year.
- Non Operating Income grew to $444000.0 in Q1 2026 per AKTX's latest filing, from -$2.0 million in the prior quarter.
- Over the last five years, Non Operating Income for AKTX reached as high as $5.6 million in Q1 2023 and fell as low as -$2.0 million in Q4 2025.
- A 5-year average of $586012.4 and a median of $279587.0 in 2022 frame the typical range for Non Operating Income.
- The largest YoY upside for Non Operating Income was 1222.94% in 2025 against a maximum downside of 362.5% in 2025.
- Year by year, Non Operating Income stood at $136174.0 in 2022, then surged by 599.11% to $952000.0 in 2023, then surged by 58.19% to $1.5 million in 2024, then plunged by 231.87% to -$2.0 million in 2025, then jumped by 122.36% to $444000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $444000.0, -$2.0 million, and -$84000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | 444,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | -1.99 Mn |
| Sep 30, 2025 | -84,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | -180,000.00 |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -109,000.00 |
| Mar 31, 2024 | 423,000.00 |
| Dec 31, 2023 | 952,000.00 |
| Sep 30, 2023 | -364,000.00 |
| Jun 30, 2023 | 615,000.00 |
| Mar 31, 2023 | 5.60 Mn |
| Jun 30, 2022 | 136,174.00 |
| Jun 30, 2021 | -16,334.00 |
| Dec 31, 2020 | 85,659.00 |
| Sep 30, 2020 | 1.16 Mn |
| Jun 30, 2020 | -1.53 Mn |
| Mar 31, 2020 | 1.18 Mn |
| Dec 31, 2019 | -3,710.00 |